Simple Summary The discovery of actionable oncogenic driver mutations in non-small-cell
lung cancer (NSCLC) has revolutionized the treatment and prognosis of this dreadful …

Non-small cell lung cancer (NSCLC) is one of the most common malignant tumors and has
high morbidity and mortality rates. Central nervous system (CNS) metastasis is one of the …

Roughly one third of non-small cell lung cancer (NSCLC) patients with epidermal growth
factor receptor tyrosine kinase inhibitor (EGFR-TKI)-sensitive mutated (EGFRm) tumors …

Brain metastases are a significant source of morbidity and mortality in patients with non-
small cell lung cancer. Historically, surgery and radiation therapy have been essential to …

The purpose of the present study was to investigate the effects of sulforaphane (SFN) on
gefitinib-resistant cell lines with a T790 mutation (PC-9/AB11). The PC-9 and PC-9/AB11 …

Lung cancer is the leading cause of cancer-related deaths worldwide. The most common
pathological type of lung cancer is non-small cell lung cancer (NSCLC). The incidence of …

Patients with non-small-cell lung cancer (NSCLC), harboring Epidermal Growth Factor
Receptor (EGFR) mutations, are more susceptible to brain metastases (BM). Comparisons of …

Non-small cell lung cancer (NSCLC), a commonly diagnosed lung cancer, is characterized
by a high incidence of metastatic spread to the brain, which adversely impacts prognosis …

Background The most frequent mode of progression in the majority of non-small cell lung
cancer (NSCLC) patients treated with Epidermal growth factor–receptor tyrosine kinase …

Background: Currently, the therapies for brain metastases of non-small cell lung cancer
(NSCLC) mainly include whole brain radiotherapy and icotinib. For exploring the efficacy …